Theralizumab
Catalogue number:
HY-P9975-5mg
Supplier:
Size:
5 mg
Product is available in:
Applications:
COVID-19-immunoregulation
Target:
CD28
Alternative Names:
TGN1412; TAB08
- Data sheet: View or download
- MSDS: View or download
- Protocol: View or download
Product Description:
Theralizumab (TGN1412) is a humanized lgG4 superagonistic anti-CD28 monoclonal antibody that directly stimulates T cells. Theralizumab can cause cytokine release syndrome (CRS). Theralizumab can be used for the research of rheumatoid arthritis[1][2].